SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Merck -- Ignore unavailable to you. Want to Upgrade?

To: Brian Malloy who wrote (528)2/20/1998 9:28:00 PM
From: EepOpp  Respond to of 1580
 
>Unfortunately, many of the analysts that comment on MRK have MBA's not backgrounds in Pharmacology...the reason MRK is really moving now is that the analysts are seeing that all their talk about MRK not having new products (which they stated spewing forth about two years ago) is wrong. Of course they probably will not come out and say that.

thanks, Brian.

I think your insight is quite accurate and this is probably what's happening. I appreciate the thoughts.

Will



To: Brian Malloy who wrote (528)2/23/1998 3:14:00 AM
From: Mephisto  Read Replies (2) | Respond to of 1580
 
I agree that MBAs know very little at all about US drug manufacturers.

Actually, I know a graduate student who did a MA thesis on MBA programs and discovered that a student who completes a MBA degree does not learn very much at all!!!

My broker told me Merck should be a core holding. It is a good company. I do not worry about its future.

I think the company will split the stock soon. The last split was four or more years ago, was it not?


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News